Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is a devastating mental illness leading to a lifetime prevalence of higher than 16% on individuals. The treatment delay and inevitable adverse effects are major limitations of current depression interventions. Emerging evidence indicates that curcumin produced significant antidepressant properties in depression in both rodents and humans without adverse effects. Therefore, it is necessary to further clarify the antidepressant actions of curcumin and the underlying mechanism in depressed patients. A total of 108 male adults aged between 31 and 59 years were systematically recruited in Tianjin Anding Hospital. Subjects were administered the Chinese version of 17-item Hamilton Depression Rating Scale and Montgomery-Asberg Depression Rating Scale that measures different scores of depressive symptoms. The subjects were asked to take 2 capsules containing either 1000 mg of curcumin or placebo soybean powder daily for 6 weeks on the basis of their current antidepressant medications. The plasma levels of interleukin 1β, tumor necrosis factor α, brain-derived neurotrophic factor, and salivary cortisol were measured by enzyme-linked immunosorbent assay before and after curcumin or placebo treatment during the 6-week procedure. Chronic supplementation with curcumin produced significant antidepressant behavioral response in depressed patients by reduction of 17-item Hamilton Depression Rating Scale and Montgomery-Asberg Depression Rating Scale scores. Furthermore, curcumin decreases inflammatory cytokines interleukin 1β and tumor necrosis factor α level, increases plasma brain-derived neurotrophic factor levels, and decreases salivary cortisol concentrations compared with placebo group. These findings indicate the potential benefits of further implications of supplementary administration of curcumin to reverse the development of depression and enhance the outcome of antidepressants treatment in major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“M ajor depressive disorder is a devastating mental illness leading to a lifetime prevalence of higher than 16% on individuals.(1) Currently, the available antidepressant drugs for the treatment of depression mainly target the monoaminergic system to achieve therapeutic responses by increase of the neurotransmitters”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“Several research confirmed that depression is linked with elevated levels of TNF-α in depressed patients than controls.(28) Furthermore, antidepressant medications reduced the levels of cytokines IL-1β.”
BackgroundInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“Patients with major depression compared with nondepressed individuals demonstrated elevations in inflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor α (TNF-α).(14,15) Preliminary data from depressed patients showed that inhibiting proinflammatory cytokines is associated with the improvement…”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Multiple biological activities of curcumin: A short review
Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.007 · Cited by 1,674
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995 · cited 1×
“Preliminary data from depressed patients showed that inhibiting proinflammatory cytokines is associated with the improvement of depressed mood and increase treatment response to conventional antidepressant intervention.(16) The fact that antidepressant medications reduced levels of cytokines IL-1β(17) raised the possi…”
BackgroundCotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Cited by
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13621 · Cited by 1,053
The therapeutic potential of curcumin: A review of clinical trials
Salehi, B., Stojanović-Radić, Z., Matejić, J., Sharifi-Rad, M., Anil Kumar, N. V., Martins, N., & Sharifi-Rad, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.016 · Cited by 495
Sahebkar, A., Cicero, A. F. G., Simental-Mendía, L. E., Aggarwal, B. B., & Gupta, S. C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.026 · Cited by 291
Yeung, K. S., Hernandez, M., Mao, J. J., Haviland, I., & Gubili, J. (2018) · Phytotherapy Research · doi:10.1002/ptr.6033 · Cited by 229
“Bitter orange blossom (Citus aurantium) (Akhlaghi et al., 2011), curcumin (Curcuma longa) (Yu et al., 2015), Melissa officinalis (Alijaniha et al., 2015), and Siberian ginseng (Eleutherococcus senticosis) (Schaffler et al., 2013) were also found to have some benefit in lowering anxiety and…”
BackgroundBayes, J., Schloss, J., & Sibbritt, D. (2020) · Advances in Nutrition · doi:10.1093/advances/nmz117 · Cited by 150
Metadata
- Authors
- Yu, J.-J., Pei, L.-B., Zhang, Y., Wen, Z.-Y., & Yang, J.-L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2015-08
- Volume
- 35
- Issue
- 4
- Pages
- 406-410
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2323433530
- Cited by
- 135
- References
- 17
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. https://app.cochat.ai/papers/10.1097/jcp.0000000000000352
- The paper
- Yu, J.-J., Pei, L.-B., Zhang, Y., Wen, Z.-Y., & Yang, J.-L. (2015). Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.